[
  {
    "file_name": "PACIRAPHARMACEUTICALS,INC.-A_RSTRATEGICLICENSING,DISTRIBUTIONANDMARKETINGAGREEMENT.txt",
    "perturbation": [
      {
        "type": "Structural Flaws - Legal Contradiction",
        "original_text": "EKR represents that it is aware of its obligations to report discounts resulting from this Agreement to the appropriate reimbursing agencies and authorities (including Medicaid and Medicare). EKR is responsible for complying with and agrees to comply with all applicable requirements, if any, in respect of providing information on such discounts to reimbursing agencies (including Medicaid and Medicare) and other entities in accordance with Applicable Laws and regulations.",
        "changed_text": "EKR represents that it is aware of its obligations to report discounts resulting from this Agreement to the appropriate reimbursing agencies and authorities. EKR is responsible for complying with and agrees to comply with all applicable requirements, if any, in respect of providing information on such discounts to other entities in accordance with Applicable Laws and regulations.",
        "explanation": "Removing '(including Medicaid and Medicare)' weakens the clarity of EKR's responsibility to report discounts to specific federal healthcare programs, which could lead to non-compliance. This alters the original intent of ensuring adherence to federal reporting requirements.",
        "contradicted_law": "42 U.S. Code \u00a7 1320a-7b - Illegal remunerations",
        "law_citation": "42 U.S.C. \u00a7 1320a-7b(b)(3)(A)",
        "law_url1": [
          "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title42-section1320a-7b"
        ],
        "law_url2": [
          "https://www.law.cornell.edu/topn/illegal_remunerations"
        ],
        "law_explanation": "By removing the explicit mention of Medicaid and Medicare, the modified text obscures the legal requirement to report discounts to these specific federal programs. 42 U.S.C. \u00a7 1320a-7b(b)(3)(A) addresses illegal remunerations, including discounts, and requires proper reporting to avoid violations of anti-kickback statutes related to federal healthcare programs. The original text ensures the company acknowledges and complies with this obligation to these specific programs, whereas the modified version is vague and could be interpreted as excluding them.",
        "location": "Section 4.20",
        "scraped_snippet_1": "This page is better viewed with a JavaScript enabled browser. Document not Found Document not found The document you were looking for does not exist. Click here to close this window, or click here to go back.",
        "scraped_snippet_2": null,
        "scrape_success": 1,
        "contradiction_score": 0.6,
        "justification": "The changed text weakens the original text by removing the explicit mention of 'Medicaid and Medicare'. The Perturbation Explanation suggests this omission dilutes the clarity of EKR's responsibility to report discounts to specific federal healthcare programs, which could lead to non-compliance. The Law Explanation supports this by stating that the modified version is vague and could be interpreted as excluding these programs, potentially violating anti-kickback statutes (42 U.S.C. \u00a7 1320a-7b(b)(3)(A)). Although Scraped Law Snippet 1 is a 'Document not Found' message and Snippet 2 is 'None', the explanations provided still suggest a weakening of the obligation, meriting a moderate contradiction score. The absence of usable snippets limits the strength of the contradiction assessment."
      },
      {
        "type": "Structural Flaws - Legal Contradiction",
        "original_text": "EKR shall obtain and maintain all necessary licenses, permits, records and authorizations required by Applicable Laws as holder of the Transferred NDA after the Agreement Date and in order to exercise the Distribution Rights and observe and comply with all Applicable Laws, ordinances, rules and regulations including, but not limited to those of the applicable Regulatory Authorities in the exercise of the Distribution Rights save insofar as PPI is required to obtain the same as holder of the Marketing Authorizations prior to the Agreement Date, or under the terms of this Agreement",
        "changed_text": "EKR shall obtain and maintain all necessary licenses, permits, records and authorizations required by Applicable Laws as holder of the Transferred NDA after the Agreement Date and in order to exercise the Distribution Rights and observe and comply with all ordinances, rules and regulations in the exercise of the Distribution Rights save insofar as PPI is required to obtain the same as holder of the Marketing Authorizations prior to the Agreement Date, or under the terms of this Agreement",
        "explanation": "By removing 'Applicable Laws' it may suggest that EKR does not need to follow these laws. This is important for NDA's to comply with all regulations.",
        "contradicted_law": "21 U.S. Code \u00a7 351 - Adulterated drugs and devices",
        "law_citation": "21 U.S.C. \u00a7 351",
        "law_url1": [
          "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title21-section351"
        ],
        "law_url2": [
          "https://www.fda.gov/regulatory-information/federal-food-drug-and-cosmetic-act-fdc-act/fdc-act-chapter-v-drugs-and-devices"
        ],
        "law_explanation": "The original text requires EKR to comply with 'Applicable Laws' as holder of the Transferred NDA, ensuring adherence to standards of drug safety and efficacy. Removing 'Applicable Laws' from the sentence creates ambiguity and undermines the explicit commitment to legal compliance. This contradicts the requirements of 21 U.S.C. \u00a7 351, which defines adulterated drugs and devices and mandates adherence to Current Good Manufacturing Practice (CGMP) regulations to prevent adulteration. By omitting the need to comply with applicable laws, the altered text creates a scenario where EKR might not adhere to the necessary CGMP standards, potentially leading to the distribution of adulterated drugs, which is in direct violation of the cited law.",
        "location": "Section 4.12",
        "scraped_snippet_1": "This page is better viewed with a JavaScript enabled browser. Document not Found Document not found The document you were looking for does not exist. Click here to close this window, or click here to go back.",
        "scraped_snippet_2": "FD&C Act Chapter V: Drugs and Devices | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links In this section : Federal Food, Drug, and Cosmetic Act (FD&C Act) Home Regulatory Information Laws Enforced by FDA Federal Food, Drug, and Cosmetic Act (FD&C Act) FD&C Act Chapter V: Drugs and Devices Federal Food, Drug, and Cosmetic Act (FD&C Act) To search the FD&C Act on the Law Revision Counsel website, you may either search by U.S. code section number or browse the Title 21 section listing . Part A - Drugs and Devices (sections 351 - 360n-1) Part B - Drugs for Rare Diseases or Conditions (sections 360aa - 360ff) Part C - Electronic Product Radiation Control (sections 360hh - 360ss) Part D - Dissemination of Treatment Information (sections 360aaa - 360aaa-6) Part E - General Provisions Relating to Drugs and Devices (sections 360bbb - 360bbb-8c) Part F - New Animal Drugs for Minor Use and Minor Species (sections 360ccc - 360ccc-2) Part G - Medical Gases (sections 360ddd to 360ddd-2) Part H - Pharmaceutical Distribution Supply Chain (sections 360eee to 360eee-4) Part I - Nonprescription Sunscreen and Other Active Ingredients (sections 360fff to 360fff-7) Part A - Drugs and Devices (sections 351 - 360n-1) FD&C Act Section Number Title Sec. 501 Sec. 351 - Adulterated drugs and devices Sec. 502 Sec. 352 - Misbranded drugs and devices Sec. 503 Sec. 353 - Exemptions and consideration for certain drugs, devices, and biological products Sec. 503A Sec. 353a - Pharmacy compounding Sec. 503A-1 Sec. 353a-1 - Enhanced Communication Sec. 503B Sec. 353b - Outsourcing facilities Sec. 503C Sec. 353c - Prereview of television advertisements Sec. 504 Sec. 354 - Veterinary feed directive drugs Sec. 505 Sec. 355 - New drugs Sec. 355-1 - Risk evaluation and mitigation strategies Sec. 505A Sec. 355a - Pediatric studies of drugs Sec. 355b - Adverse-event reporting Sec. 505B Sec. 355c - Research into pediatric uses for drugs and biological products Sec. 355c-1 - Report Sec. 505C Sec. 355d - Internal committee for review of pediatric plans, assessments, deferrals, and waivers Sec. 505D Sec. 355e - Pharmaceutical security Sec. 506 Sec. 356 - Fast track products Sec. 355f - Extension of exclusivity period for new qualified infectious disease products Sec. 356. Expedited approval of drugs for serious or life-threatening diseases or conditions Sec. 356-1 - Accelerated approval of priority countermeasures Sec. 506A Sec. 356a - Manufacturing changes Sec. 506B Sec. 356b - Reports of postmarketing studies Sec. 506C Sec. 356c - ",
        "scrape_success": 2,
        "contradiction_score": 0.7,
        "justification": "The changed text removes 'Applicable Laws', weakening EKR's obligation to comply with all relevant laws. The Law Explanation suggests this could lead to violations of 21 U.S.C. \u00a7 351 regarding adulterated drugs. Scraped Law Snippet 2 mentions 'Sec. 351 - Adulterated drugs and devices' within the 'FD&C Act Chapter V: Drugs and Devices'. Although Snippet 1 is a 'Document not Found' error, Snippet 2 confirms the existence of a law concerning adulterated drugs. By removing 'Applicable Laws,' the modified contract creates a potential loophole for non-compliance with these regulations, increasing the risk of distributing adulterated drugs and devices. The contradiction score reflects this increased risk and the connection to the identified law."
      },
      {
        "type": "Structural Flaws - Legal Contradiction",
        "original_text": "During the Term, PPI shall at its own cost and expense cooperate fully and assist EKR with the preparation of any necessary submissions to any of the Regulatory Authorities in the Territory for the development and approval or supplemental approval(s) of the Products, including, but not limited to, by providing access to all PPI Know-How, the drug master file and any other information necessary for approval or supplemental approval of the Product in any country of the Territory. In addition, PPI shall cooperate fully in participating in interactions with the appropriate Regulatory Authorities including FDA related to such product development so as to enable EKR to fully exploit the Distribution Rights granted hereunder.",
        "changed_text": "During the Term, PPI shall at its own cost and expense cooperate fully and assist EKR with the preparation of any necessary submissions to any of the Regulatory Authorities in the Territory for the development and approval or supplemental approval(s) of the Products, including, but not limited to, by providing access to all PPI Know-How, the drug master file and any other information necessary for approval or supplemental approval of the Product in any country of the Territory.",
        "explanation": "Removing 'In addition, PPI shall cooperate fully in participating in interactions with the appropriate Regulatory Authorities including FDA related to such product development so as to enable EKR to fully exploit the Distribution Rights granted hereunder.' weakens PPI's commitment to cooperate with EKR in interactions with Regulatory Authorities, including the FDA. This could hinder EKR's ability to obtain necessary approvals and effectively exploit its distribution rights. By doing so, can delay important distribution.",
        "contradicted_law": "21 CFR Part 314 - Applications for FDA Approval to Market a New Drug",
        "law_citation": "21 CFR \u00a7 314.50(d)(5)",
        "law_url1": [
          "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/section-314.50"
        ],
        "law_url2": [
          "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-under-fdas-user-fee-programs"
        ],
        "law_explanation": "21 CFR \u00a7 314.50(d)(5) requires comprehensive data and information to support a New Drug Application (NDA), including active cooperation and communication with the FDA. The original text ensures PPI's full cooperation with EKR in interactions with regulatory bodies, including the FDA, to facilitate product development and distribution. By removing the explicit commitment to cooperate in FDA-related interactions, the modified text undermines the assurance of collaborative effort. This could impede EKR's ability to provide the FDA with all necessary data, information, and responses during the NDA approval process. This lack of cooperation could lead to delays or rejection of the application, directly conflicting with the regulatory requirements for NDA approval under 21 CFR \u00a7 314.50(d)(5).",
        "location": "Section 3.14",
        "scraped_snippet_1": "eCFR :: 21 CFR 314.50 -- Content and format of an NDA. Site Feedback You are using an unsupported browser \u00d7 You are using an unsupported browser. This web site is designed for the current versions of Microsoft Edge, Google Chrome, Mozilla Firefox, or Safari. \u00d7 Site Feedback The Office of the Federal Register publishes documents on behalf of Federal agencies but does not have any authority over their programs. We recommend you directly contact the agency associated with the content in question. If you have comments or suggestions on how to improve the www.ecfr.gov website or have questions about using www.ecfr.gov, please choose the 'Website Feedback' button below. Website Feedback If you would like to comment on the current content, please use the 'Content Feedback' button below for instructions on contacting the issuing agency Content Feedback If you have questions for the Agency that issued the current document please contact the agency directly. \u00d7 Website Feedback * Your Name * Email Attachment * How can we help you? * I am requesting technical help or providing website feedback This contact form is only for website help or website suggestions. If you have questions or comments regarding a published document please contact the publishing agency. Comments or questions about document content can not be answered by OFR staff. Please do not provide confidential information or personal data. Browse Titles Agencies Incorporation by Reference Recent Updates Search Recent Changes Corrections Reader Aids Reader Aids Home Using the eCFR Point-in-Time System Understanding the eCFR Government Policy and OFR Procedures Developer Resources My eCFR My Subscriptions Sign Out Sign In / Sign Up Sign In / Sign Up Hi, Sign Out eCFR The Electronic Code of Federal Regulations Enhanced Content :: FR Reference Enhanced content is provided to the user to provide additional context. Enhanced Content :: FR Reference Title 21 This content is from the eCFR and is authoritative but unofficial. Displaying title 21",
        "scraped_snippet_2": null,
        "scrape_success": 1,
        "contradiction_score": 0.7,
        "justification": "The original text explicitly required PPI to cooperate fully in interactions with Regulatory Authorities, including the FDA, to enable EKR to exploit its distribution rights. The changed text removes this explicit commitment. The Law Explanation points to 21 CFR \u00a7 314.50(d)(5) as requiring comprehensive data and cooperation. Scraped Law Snippet 1 identifies 21 CFR 314.50 as pertaining to the \"Content and format of an NDA.\" While Scraped Law Snippet 1 does not provide the full text of the law, the Law Explanation argues that removing the explicit cooperation clause could impede EKR's ability to provide necessary data to the FDA, potentially leading to delays or rejection of the NDA. The removal of the explicit cooperation, especially regarding FDA interactions, creates a potential contradiction as it weakens the commitment to providing the necessary support for NDA approval. A score of 0.7 is appropriate as the law requires comprehensive data and information to support an NDA, and removing the explicit cooperation clause weakens the assurance that EKR will receive the necessary support from PPI to comply with the regulatory requirement."
      }
    ]
  }
]